Framixa (Spray) Instructions for Use
Marketing Authorization Holder
Iris, LLC (Russia)
Manufactured By
YUGPHARM, LLC (Russia)
ATC Code
R01AX08 (Framycetin)
Active Substance
Framycetin (Rec.INN WHO registered)
Dosage Form
| Framixa | Nasal spray 1.25% |
Dosage Form, Packaging, and Composition
Nasal spray
| 1 ml | |
| Framycetin sulfate | 12.5 mg |
15 ml – bottles – cardboard packs – By prescription
Clinical-Pharmacological Group
Antibacterial drug for topical use in ENT practice
Pharmacotherapeutic Group
Drugs for the treatment of nasal diseases; decongestants and other preparations for topical use; other drugs for the treatment of nasal diseases
Pharmacological Action
An antibiotic from the aminoglycoside group with a broad spectrum of action for topical use in otorhinolaryngology. It acts bactericidally, damages the cytoplasmic membrane, disrupts the flow of metabolites inside the cell and causes rapid death of microorganisms.
It is active against most gram-positive and gram-negative bacteria: Staphylococcus aureus, Staphylococcus spp. (including strains resistant to other antibiotics), some strains of Streptococcus spp., Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Klebsiella spp., Haemophilus influenzae, Salmonella spp., Shigella spp., Enterobacter spp., Proteus spp., Serratia marcescens, Pasteurella spp., Vibrio spp., Borrelia, Leptospira spp., Mycobacterium tuberculosis (including strains resistant to streptomycin), which cause the development of infectious processes in the upper respiratory tract.
Treponema spp., some strains of Streptococcus spp., and anaerobic microorganisms are resistant to framycetin.
Pharmacokinetics
When applied topically, it has low systemic absorption.
Indications
As part of combination therapy for infectious and inflammatory diseases of the upper respiratory tract, including: rhinitis, rhinopharyngitis, sinusitis (in the absence of septal damage). Prevention and treatment of inflammatory processes after surgical interventions.
ICD codes
| ICD-10 code | Indication |
| J00 | Acute nasopharyngitis (common cold) |
| J01 | Acute sinusitis |
| J02 | Acute pharyngitis |
| J31.0 | Chronic rhinitis (including ozaena, atrophic and hypertrophic rhinitis) |
| J31.2 | Chronic pharyngitis |
| J32 | Chronic sinusitis |
| Z29.2 | Other prophylactic chemotherapy (administration of antibiotics for prophylactic purposes) |
| ICD-11 code | Indication |
| CA00 | Acute nasopharyngitis |
| CA01 | Acute rhinosinusitis |
| CA02.Z | Acute pharyngitis, unspecified |
| CA09.0 | Chronic rhinitis |
| CA09.2 | Chronic pharyngitis |
| CA0A.Z | Chronic rhinosinusitis, unspecified |
| QC05.Y | Other specified prophylactic measures |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Administer intranasally only. Clear nasal passages prior to application.
For adults and children: administer one spray into each nostril. The frequency of administration is three to six times per day.
Adhere strictly to a maximum treatment duration of seven days. Do not exceed this duration.
For postoperative prophylaxis and treatment: initiate use as directed by a physician following the surgical procedure.
Discontinue use immediately upon resolution of infectious and inflammatory symptoms. Do not use for prolonged periods.
If no clinical improvement is observed within three to four days, reevaluate the diagnosis and treatment strategy.
Avoid contact with eyes. If contact occurs, rinse thoroughly with water.
Adverse Reactions
Possible: allergic reactions.
Contraindications
Hypersensitivity to antibiotics of the aminoglycoside group; pregnancy, breastfeeding period.
Framycetin should not be used for washing the paranasal sinuses.
Use in Pregnancy and Lactation
Contraindicated for use during pregnancy and breastfeeding.
Pediatric Use
Can be used in children according to indications, in recommended doses.
Special Precautions
During treatment, the appearance of resistant strains of microorganisms is possible.
Aminoglycoside antibiotics can cause reversible, partial or complete deafness and have a nephrotoxic effect when used systemically and when applied topically to open wounds or damaged skin. These effects are dose-dependent and are enhanced in cases of impaired liver or kidney function. The risk of their occurrence should be taken into account in case of topical application of high doses of the drug in children. Therapy should not be continued after the symptoms disappear.
Framycetin should not be used simultaneously with other antibiotics that have ototoxic and nephrotoxic effects ( streptomycin, monomycin, kanamycin, gentamicin).
Storage Conditions
Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Rx Only
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical Disclaimer
Picamilon pills 50mg, 60pcs
Ingavirin capsules 90mg, 10pcs
Cerebrolysin, solution for injection 2ml ampoules 10pcs
Fenotropil pills 100mg, 60pcs
Belosalic, lotion solution for external use spray 100ml
Arbidol, capsules 100mg, 40pcs
Phenibut-Vertex pills 250mg, 20pcs
Mildronate capsules 500mg, 90pcs
Actovegin pills 200mg, 50pcs
Nootropil pills 800mg, 30pcs
Kagocel pills 12mg, 30pcs
Noopept, pills 10mg, 50pcs
Cortexin, 10mg, 5ml, 10pcs 